Omada Health, Inc. (NASDAQ:OMDA - Get Free Report) has been assigned an average recommendation of "Buy" from the seven ratings firms that are currently covering the firm, MarketBeat Ratings reports. Seven analysts have rated the stock with a buy rating. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $23.86.
A number of brokerages have weighed in on OMDA. Morgan Stanley assumed coverage on shares of Omada Health in a research note on Tuesday, July 1st. They set an "overweight" rating and a $25.00 target price for the company. Evercore ISI increased their price objective on shares of Omada Health from $21.00 to $23.00 and gave the stock an "outperform" rating in a research report on Wednesday, July 9th. Canaccord Genuity Group initiated coverage on shares of Omada Health in a research note on Tuesday, July 1st. They issued a "buy" rating and a $27.00 target price on the stock. Barclays began coverage on shares of Omada Health in a research note on Tuesday, July 1st. They issued an "overweight" rating and a $21.00 target price for the company. Finally, Wall Street Zen raised shares of Omada Health to a "hold" rating in a report on Monday, June 16th.
View Our Latest Research Report on OMDA
Omada Health Stock Performance
OMDA stock traded down $0.16 during midday trading on Friday, reaching $18.42. 135,321 shares of the stock were exchanged, compared to its average volume of 793,722. Omada Health has a 52 week low of $14.14 and a 52 week high of $28.40.
About Omada Health
(
Get Free ReportOmada's mission is to bend the curve. Our hope is that, one day, tomorrow's epidemiologists will notice a bend in disease curves, wonder what might be happening, and conclude that part of that impact has been Omada. As part of that mission, we strive to inspire and enable people to make lasting health changes on their own terms.
See Also

Before you consider Omada Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Omada Health wasn't on the list.
While Omada Health currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.